ADMP Adamis Pharmaceuticals Corporation Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

ADMP [NASD]

Adamis Pharmaceuticals Corporation

Healthcare | Drug Manufacturers - Specialty & Generic | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.52	Insider Own	1.30%	Shs Outstand	73.83M	Perf Week	-14.12%
Market Cap	76.13M	Forward P/E	-	EPS next Y	-0.15	Insider Trans	-8.65%	Shs Float	72.96M	Perf Month	12.54%
Income	-34.20M	PEG	-	EPS next Q	-0.05	Inst Own	5.50%	Short Float	5.28%	Perf Quarter	-24.44%
Sales	20.00M	P/S	3.81	EPS this Y	44.90%	Inst Trans	-0.32%	Short Ratio	0.70	Perf Half Y	95.08%
Book/sh	0.31	P/B	2.56	EPS next Y	63.40%	ROA	-73.70%	Target Price	1.25	Perf Year	7.22%
Cash/sh	0.08	P/C	9.64	EPS next 5Y	-	ROE	-103.20%	52W Range	0.27 - 1.51	Perf YTD	13.28%
Dividend	-	P/FCF	-	EPS past 5Y	9.10%	ROI	-76.90%	52W High	-47.46%	Beta	2.10
Dividend %	-	Quick Ratio	0.80	Sales past 5Y	-	Gross Margin	17.30%	52W Low	193.85%	ATR	0.07
Employees	131	Current Ratio	1.00	Sales Q/Q	-32.80%	Oper. Margin	-	RSI (14)	46.61	Volatility	7.86% 8.64%
Optionable	Yes	Debt/Eq	0.23	EPS Q/Q	6.20%	Profit Margin	-	Rel Volume	0.29	Prev Close	0.81
Shortable	Yes	LT Debt/Eq	0.09	Earnings	-	Payout	-	Avg Volume	5.50M	Price	0.79
Recom	2.70	SMA20	-6.11%	SMA50	-1.18%	SMA200	19.96%	Volume	1,572,974	Change	-2.36%

May-13-20

Upgrade

Maxim Group

Hold → Buy

$1.50

Feb-27-20

Downgrade

Dawson James

Buy → Neutral

Nov-26-19

Downgrade

Raymond James

Outperform → Mkt Perform

Jul-16-19

Downgrade

B. Riley FBR

Neutral → Sell

$1.90 → $1.10

Nov-12-18

Downgrade

B. Riley FBR

Buy → Neutral

$7.50 → $2.50

May-11-18

Reiterated

Maxim Group

Buy

$5 → $10

Mar-23-18

Reiterated

B. Riley FBR, Inc.

Buy

$6.25 → $7.50

Dec-05-17

Reiterated

Maxim Group

Buy

$13 → $14

Oct-04-17

Resumed

B. Riley & Co.

Buy

$9.50

Jul-21-16

Reiterated

Maxim Group

Buy

$17 → $10

Dec-01-15

Initiated

Maxim Group

Buy

$16

May-29-15

Initiated

Mizuho

Buy

$10

Jan-28-14

Initiated

CRT Capital

Buy

$15

Oct-12-20 10:24AM	Looking Into Adamis Pharmaceuticals's Return On Capital Employed Benzinga
Sep-18-20 09:00AM	Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -9.41%
Sep-17-20 04:05PM	Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Sep-16-20 09:23AM	New Strong Sell Stocks for September 16th Zacks
Sep-03-20 04:05PM	Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders GlobeNewswire +7.27%
Aug-25-20 09:00AM	Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders and Proposals GlobeNewswire
Aug-21-20 09:00AM	Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders GlobeNewswire
Aug-17-20 05:55PM	Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:40PM	Adamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update GlobeNewswire
Aug-14-20 09:00AM	Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19 GlobeNewswire -6.86%
Aug-06-20 12:30PM	Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Aug-05-20 04:05PM	Adamis Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement GlobeNewswire
Jul-23-20 09:00AM	Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock? Zacks
Jul-01-20 09:00AM	Adamis Pharmaceuticals Provides Update on SYMJEPI Products GlobeNewswire
Jun-18-20 09:00AM	Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose GlobeNewswire -5.12%
Jun-15-20 09:00AM	Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19 GlobeNewswire +7.63%
May-27-20 09:00AM	Adamis Pharmaceuticals Announces Publication of Pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone GlobeNewswire
May-25-20 10:37AM	Edited Transcript of ADMP earnings conference call or presentation 18-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-18-20 04:35PM	Adamis Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update GlobeNewswire +6.90%
09:00AM	Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA GlobeNewswire
May-15-20 09:00AM	Adamis Pharmaceuticals Schedules First Quarter 2020 Earnings Conference Call and Business Update GlobeNewswire
May-12-20 08:06AM	The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings Benzinga
May-11-20 08:35PM	Adamis Pharmaceuticals Provides Update on SYMJEPI Products and Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI Products GlobeNewswire
Apr-29-20 12:00PM	Adamis (ADMP) Moves to Strong Buy: Rationale Behind the Upgrade Zacks +8.05%
Apr-23-20 09:00AM	Adamis Pharmaceuticals Announces Publication Demonstrating PET Scan Results of Higher Dose Naloxone in Monkeys GlobeNewswire +5.09%
Apr-21-20 09:00AM	Adamis Pharmaceuticals Announces Production of Additional Drugs by its US Compounding Subsidiary to Aid in the COVID-19 Pandemic GlobeNewswire
Apr-15-20 04:05PM	Adamis Pharmaceuticals Announces Receipt of Loan Proceeds Under Paycheck Protection Program GlobeNewswire
Apr-01-20 09:00AM	Adamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 Pandemic GlobeNewswire +17.10%
Mar-30-20 04:40PM	Adamis Pharmaceuticals Announces 2019 Financial Results and Business Update GlobeNewswire
Feb-21-20 09:15AM	Adamis Pharmaceuticals Announces Pricing of $6.7 Million Registered Direct Offering GlobeNewswire -8.04%
Feb-19-20 09:00AM	Adamis Pharmaceuticals Provides Update Regarding ZIMHI GlobeNewswire -9.47%
Jan-03-20 09:31PM	Edited Transcript of ADMP earnings conference call or presentation 12-Nov-19 10:00pm GMT Thomson Reuters StreetEvents +10.91%
Dec-23-19 03:59PM	Adamis Pharmaceuticals Corporation (ADMP): Are Hedge Funds Right About This Stock? Insider Monkey +13.65%
Dec-19-19 09:00AM	Adamis Pharmaceuticals Provides an Update on ZIMHI GlobeNewswire +7.32%
Nov-27-19 05:09PM	Maxims Bullish Stance on Adamis (ADMP) Stock Comes to an End TipRanks +6.90%
Nov-25-19 03:16PM	Adamis shares tumble after letter from FDA MarketWatch -50.96%
08:44AM	UPDATE 1-FDA declines to approve Adamis Pharma's Zimhi to treat opioid overdose Reuters
08:12AM	FDA declines to approve Adamis Pharma's Zimhi to treat opioid overdose Reuters
08:00AM	Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI GlobeNewswire
Nov-18-19 09:00AM	Adamis Pharmaceuticals Announces Publication of Comparative Pharmacokinetics of Community Use Naloxone Formulations GlobeNewswire
Nov-12-19 07:05PM	Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Misses Revenue Estimates Zacks -6.65%
04:28PM	Adamis Pharmaceuticals Announces Third Quarter 2019 Financial Results and Business Update GlobeNewswire
Nov-07-19 08:54AM	Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options Zacks -7.32%
Nov-06-19 04:05PM	Adamis Pharmaceuticals Schedules Third Quarter 2019 Earnings Conference Call and Business Update GlobeNewswire +26.32%
Nov-05-19 06:53AM	The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment Benzinga
Nov-04-19 08:00PM	Adamis Pharmaceuticals Provides Regulatory Update for Its Higher Dose Naloxone Pre-Filled Syringe GlobeNewswire
Nov-01-19 10:30AM	Will Adamis Pharmaceuticals (ADMP) Report Negative Q3 Earnings? What You Should Know Zacks -9.38%
Oct-18-19 06:26AM	Could The Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ownership Structure Tell Us Something Useful? Simply Wall St.
Oct-08-19 09:00AM	Adamis Pharmaceuticals Announces Presentation of ZIMHI data at IHV Scientific Meeting GlobeNewswire
Oct-01-19 09:00AM	Adamis Pharmaceuticals Announces Commercial Partnership with Emerge Health for SYMJEPI® in Australia and New Zealand GlobeNewswire
Sep-26-19 09:00AM	Adamis Pharmaceuticals Announces Presentation Pertaining to Its High Dose Naloxone Product Candidate at IHV Scientific Meeting GlobeNewswire
Sep-12-19 06:20AM	Adamis Pharmaceuticals Corporation (NASDAQ:ADMP): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St. -5.44%
Sep-03-19 09:00AM	Adamis Pharmaceuticals Provides Update for Naloxone Product Candidate GlobeNewswire -10.54%
Aug-28-19 09:00AM	Adamis Pharmaceuticals Provides Launch and Marketing Update for SYMJEPI GlobeNewswire
Aug-26-19 04:05PM	Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors GlobeNewswire
Aug-19-19 08:48AM	Edited Transcript of ADMP earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-14-19 09:00AM	Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary GlobeNewswire -6.09%
Aug-08-19 08:40PM	Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:30PM	Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update GlobeNewswire
Aug-07-19 06:38AM	Did Changing Sentiment Drive Adamis Pharmaceuticals's (NASDAQ:ADMP) Share Price Down A Painful 73%? Simply Wall St.
Aug-05-19 09:00AM	Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update GlobeNewswire
Aug-02-19 10:30AM	Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Aug-01-19 09:00AM	Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire -13.91%
Jul-31-19 04:05PM	Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
Jul-26-19 09:13AM	Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings? Zacks
09:12AM	Masimo (MASI) to Report Q2 Earnings: What's in the Offing? Zacks
Jul-25-19 07:37AM	What's in the Offing for DexCom's (DXCM) Earnings in Q2? Zacks
Jul-24-19 09:00AM	Adamis Pharmaceuticals Provides Update on Litigation with Belcher Pharmaceuticals GlobeNewswire +10.81%
Jul-18-19 01:52PM	Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc. GlobeNewswire
Jul-09-19 08:30AM	Adamis Pharmaceuticals Provides Update on U.S. Retail Launch of SYMJEPI GlobeNewswire +10.85%
07:45AM	Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage Reuters
Jun-27-19 09:00AM	Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc. GlobeNewswire
Jun-20-19 10:02AM	Have Insiders Been Selling Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Shares? Simply Wall St.
Jun-11-19 09:00AM	Adamis Pharmaceuticals Provides Update on Its Higher Dose Naloxone Injection Product GlobeNewswire
May-21-19 08:30AM	Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product GlobeNewswire -12.09%
May-14-19 09:00AM	Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product GlobeNewswire
May-13-19 09:06PM	Edited Transcript of ADMP earnings conference call or presentation 9-May-19 9:00pm GMT Thomson Reuters StreetEvents -5.10%
May-09-19 05:55PM	Adamis Pharmaceuticals (ADMP) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:51PM	Adamis: 1Q Earnings Snapshot Associated Press
04:30PM	Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update GlobeNewswire
May-07-19 09:00AM	Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update GlobeNewswire
May-02-19 10:32AM	Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Mar-15-19 04:39PM	Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update GlobeNewswire
07:39AM	The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA Benzinga
Mar-14-19 04:55PM	Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate Business Wire
10:30AM	Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
Mar-13-19 11:51AM	Before You Buy Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), Consider Its Volatility Simply Wall St.
Feb-27-19 08:13AM	The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings Benzinga
Feb-26-19 06:54PM	Adamis Provides Regulatory Update on Sublingual Tadalafil GlobeNewswire
Feb-20-19 09:00AM	Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic GlobeNewswire
Jan-23-19 01:51PM	Is Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Excessively Paying Its CEO? Simply Wall St.
Jan-17-19 08:06AM	The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US Benzinga +9.51%
07:55AM	Today's Research Reports on Trending Tickers: Adamis Pharmaceuticals and Biocept ACCESSWIRE
Jan-16-19 04:48PM	Adamis stock surges on release of EpiPen alternative MarketWatch
04:18PM	Adamis Commercial Partner Launches SYMJEPI (epinephrine) in the US GlobeNewswire
Jan-03-19 07:30AM	Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-02-19 10:21AM	Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James Benzinga +6.22%
Dec-31-18 04:02PM	Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Naloxone Pre-Filled Syringe GlobeNewswire +7.14%
08:59AM	4 Pharma Stocks Gaining Speed on Monday (12/31/18) ACCESSWIRE
Dec-28-18 07:46PM	Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Tadalafil Sublingual Tablet GlobeNewswire

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hopkins Robert O	Chief Financial Officer	Sep 29	Sale	0.80	20,000	16,000	274,781	Oct 01 06:34 PM
Marguglio David J.	SVP and Chief Business Officer	Sep 29	Sale	0.80	20,000	16,000	308,539	Oct 01 06:33 PM
Marguglio David J.	SVP and Chief Business Officer	Aug 18	Sale	0.87	8,749	7,648	328,539	Aug 20 05:41 PM
Hopkins Robert O	Chief Financial Officer	Aug 18	Sale	0.87	7,418	6,484	294,781	Aug 20 05:38 PM
CARLO DENNIS J PHD	President & CEO	Aug 18	Sale	0.87	10,929	9,553	299,247	Aug 20 05:37 PM
Moss Ronald B.	Chief Medical Officer	Aug 18	Sale	0.87	8,749	7,648	226,373	Aug 20 05:36 PM
Daniels Karen K.	VP of Operations	Aug 18	Sale	0.87	5,480	4,790	140,664	Aug 20 05:34 PM
Daniels Karen K.	VP of Operations	May 19	Sale	0.56	4,855	2,719	146,144	May 20 04:07 PM
CARLO DENNIS J PHD	President & CEO	May 18	Sale	0.56	9,913	5,552	310,176	May 20 04:06 PM
Hopkins Robert O	Chief Financial Officer	May 18	Sale	0.56	6,532	3,659	302,199	May 20 04:10 PM
Marguglio David J.	SVP and Chief Business Officer	May 18	Sale	0.56	7,734	4,332	337,288	May 20 04:09 PM
Moss Ronald B.	Chief Medical Officer	May 18	Sale	0.56	7,736	4,333	235,122	May 20 04:08 PM
Moss Ronald B.	Chief Medical Officer	Mar 18	Sale	0.34	10,337	3,479	242,858	Mar 19 06:41 PM
Marguglio David J.	SVP and Chief Business Officer	Mar 18	Sale	0.34	10,337	3,479	325,022	Mar 19 06:40 PM
Hopkins Robert O	Chief Financial Officer	Mar 18	Sale	0.34	8,749	2,945	308,731	Mar 19 06:39 PM
Daniels Karen K.	VP of Operations	Mar 18	Sale	0.34	6,461	2,175	150,999	Mar 19 06:36 PM
CARLO DENNIS J PHD	President & CEO	Mar 18	Sale	0.34	10,645	3,583	320,089	Mar 19 06:35 PM
CARLO DENNIS J PHD	President & CEO	Feb 24	Sale	0.60	12,436	7,505	330,734	Feb 26 06:34 PM
Marguglio David J.	SVP and Chief Business Officer	Feb 24	Sale	0.60	9,948	6,004	335,359	Feb 26 06:01 PM
Hopkins Robert O	Chief Financial Officer	Feb 24	Sale	0.60	8,420	5,081	317,480	Feb 26 06:00 PM
Daniels Karen K.	VP of Operations	Feb 24	Sale	0.60	6,229	3,759	157,460	Feb 26 05:59 PM
Moss Ronald B.	Chief Medical Officer	Feb 24	Sale	0.06	6,229	396	253,195	Feb 26 05:58 PM
Daniels Karen K.	VP of Operations	Nov 18	Sale	0.83	5,421	4,499	163,689	Nov 20 05:48 PM
Marguglio David J.	SVP and Chief Business Officer	Nov 18	Sale	0.87	8,283	7,197	365,307	Nov 20 05:47 PM
CARLO DENNIS J PHD	President & CEO	Nov 18	Sale	0.84	10,760	8,999	343,170	Nov 20 05:44 PM
Hopkins Robert O	Chief Financial Officer	Nov 18	Sale	0.83	7,347	6,099	325,900	Nov 20 05:50 PM
Moss Ronald B.	Chief Medical Officer	Nov 18	Sale	0.85	8,448	7,198	259,424	Nov 20 05:49 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience